

# Giovanni Musso

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6496164/publications.pdf>

Version: 2024-02-01

76  
papers

9,921  
citations

76326

40  
h-index

76900

74  
g-index

79  
all docs

79  
docs citations

79  
times ranked

13204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early prolonged prone position in noninvasively ventilated patients with SARS-CoV-2-related moderate-to-severe hypoxemic respiratory failure: clinical outcomes and mechanisms for treatment response in the PRO-NIV study. <i>Critical Care</i> , 2022, 26, 118.	5.8	21
2	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	3.0	41
3	Diabetic ketoacidosis with SGLT2 inhibitors. <i>BMJ</i> , The, 2020, 371, m4147.	6.0	42
4	Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression. <i>PLoS Medicine</i> , 2020, 17, e1003461.	8.4	28
5	Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1745.	4.1	39
6	Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2019, 365, l1328.	2.3	74
7	Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. <i>American Journal of Gastroenterology</i> , 2019, 114, 607-619.	0.4	22
8	Gut microbiota, hypertension and chronic kidney disease: Recent advances. <i>Pharmacological Research</i> , 2019, 144, 390-408.	7.1	54
9	MICROBIOTA INTESTINALE E RISCHIO CARDIOVASCOLARE. <i>Il Diabete</i> , 2019, 3, .	0.0	0
10	Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 387-401.	8.7	36
11	Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?. <i>Current Diabetes Reports</i> , 2018, 18, 98.	4.2	138
12	Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 282-302.e8.	1.3	216
13	Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>JAMA Internal Medicine</i> , 2017, 177, 633.	5.1	339
14	TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. <i>Journal of Lipid Research</i> , 2017, 58, 1221-1229.	4.2	40
15	MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. <i>Human Molecular Genetics</i> , 2017, 26, 1747-1758.	2.9	20
16	Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". <i>Circulation</i> , 2017, 136, 1563-1564.	1.6	0
17	New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 972-985.	4.4	26
18	Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Diabetes Care</i> , 2016, 39, 1830-1845.	8.6	129

#	ARTICLE	IF	CITATIONS
19	Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 249-274.	46.4	365
20	TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD. <i>Journal of Hepatology</i> , 2016, 64, 979-981.	3.7	15
21	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 106-120.	6.1	37
22	Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: All that is gold does not glitter, not all those who wander are lost. <i>Hepatology</i> , 2015, 61, 2104-2106.	7.3	8
23	OSAS-Related Inflammatory Mechanisms of Liver Injury in Nonalcoholic Fatty Liver Disease. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	41
24	Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 310-318.	4.7	6
25	Chronic kidney disease (CKD) and NAFLD: Time for awareness and screening. <i>Journal of Hepatology</i> , 2015, 62, 983-984.	3.7	10
26	Trials of obeticholic acid for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015, 386, 27.	13.7	6
27	Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. <i>Thorax</i> , 2015, 70, 769-781.	5.6	47
28	Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. <i>Trends in Molecular Medicine</i> , 2015, 21, 645-662.	6.7	96
29	Obstructive Sleep Apnea Syndrome Affects Liver Histology and Inflammatory Cell Activation in Pediatric Nonalcoholic Fatty Liver Disease, Regardless of Obesity/Insulin Resistance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 66-76.	5.6	103
30	Consuming More of Daily Caloric Intake at Dinner Predisposes to Obesity. A 6-Year Population-Based Prospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e108467.	2.5	117
31	Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. <i>PLoS Medicine</i> , 2014, 11, e1001680.	8.4	507
32	Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD?. <i>Diabetologia</i> , 2014, 57, 850-855.	6.3	10
33	Interactions among bone, liver, and adipose tissue predisposing to diabetes and fatty liver. <i>Trends in Molecular Medicine</i> , 2013, 19, 522-535.	6.7	68
34	Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. <i>Progress in Lipid Research</i> , 2013, 52, 175-191.	11.6	326
35	Sterol Regulatory Element-Binding Factor 2 ( <i>SREBF-2</i> ) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism. <i>Diabetes</i> , 2013, 62, 1109-1120.	0.6	61
36	Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 895-906.	4.7	43

#	ARTICLE	IF	CITATIONS
37	Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients?. <i>Current Pharmaceutical Design</i> , 2013, 19, 5297-313.	1.9	11
38	NAFLD: Old Issues and Emerging Concepts. <i>Seminars in Liver Disease</i> , 2012, 32, 001-002.	3.6	1
39	Obstructive Sleep Apnea-Hypopnea Syndrome and Nonalcoholic Fatty Liver Disease: Emerging Evidence and Mechanisms. <i>Seminars in Liver Disease</i> , 2012, 32, 049-064.	3.6	71
40	Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 962-969.	4.7	50
41	Probiotics, Prebiotics, Energy Balance, and Obesity. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 843-854.	2.2	34
42	A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. <i>Annals of Medicine</i> , 2012, 44, 375-393.	3.8	247
43	Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block. <i>Endocrine</i> , 2012, 42, 237-239.	2.3	14
44	Diagnostic accuracy of adipose insulin resistance index and visceral adiposity index for progressive liver histology and cardiovascular risk in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2012, 56, 788-789.	7.3	27
45	Nonalcoholic steatohepatitis versus steatosis: Adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. <i>Hepatology</i> , 2012, 56, 933-942.	7.3	110
46	Gut Microbiota as a Modulator of Cardiometabolic Risk: Mechanisms and Therapeutic Implications. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 71-79.	2.0	2
47	The Finnish Diabetes Risk Score (FINDRISC) and other non-invasive scores for screening of hepatic steatosis and associated cardiometabolic risk. <i>Annals of Medicine</i> , 2011, 43, 413-417.	3.8	15
48	Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 1325-1365.	5.4	128
49	Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. <i>Annals of Medicine</i> , 2011, 43, 617-649.	3.8	1,098
50	Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes. <i>Annual Review of Medicine</i> , 2011, 62, 361-380.	12.2	515
51	Need for a three-focused approach to nonalcoholic fatty liver disease. <i>Hepatology</i> , 2011, 53, 1773-1773.	7.3	9
52	Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease. <i>Current Opinion in Lipidology</i> , 2011, 22, 489-496.	2.7	41
53	Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis. <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1033-1042.	4.7	21
54	Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. <i>Current Opinion in Lipidology</i> , 2010, 21, 76-83.	2.7	151

#	ARTICLE	IF	CITATIONS
55	Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease. Annual Review of Medicine, 2010, 61, 375-392.	12.2	77
56	Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation. Hepatology, 2010, 51, 715-717.	7.3	32
57	A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 79-104.	7.3	492
58	Lipoprotein metabolism mediates the association of MTP polymorphism with $\beta$ -cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. Journal of Nutritional Biochemistry, 2010, 21, 834-840.	4.2	36
59	Obesity, Diabetes, and Gut Microbiota. Diabetes Care, 2010, 33, 2277-2284.	8.6	557
60	Transcription Factor 7-Like 2 (TCF7L2) Polymorphism and Hyperglycemia in an Adult Italian Population-Based Cohort. Diabetes Care, 2010, 33, 1233-1235.	8.6	15
61	Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. American Journal of Clinical Nutrition, 2009, 89, 558-567.	4.7	90
62	Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology, 2009, 49, 426-435.	7.3	75
63	Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression?. Journal of Gastroenterology, 2009, 44, 476-482.	5.1	16
64	Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research, 2009, 48, 1-26.	11.6	564
65	Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology, 2008, 47, 1167-1177.	7.3	119
66	Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?. Diabetes Care, 2008, 31, 562-568.	8.6	185
67	Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Annals of Medicine, 2008, 40, 383-394.	3.8	21
68	Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. American Journal of Clinical Nutrition, 2007, 86, 661-671.	4.7	52
69	Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?. Hepatology, 2007, 45, 1097-1107.	7.3	112
70	Association between postprandial LDL conjugated dienes and the severity of liver fibrosis in NASH. Hepatology, 2006, 43, 1169-1170.	7.3	10
71	The Postprandial Phase as a Link Between Systemic Lipid Peroxidation and Liver Injury in NASH This article has been retracted. American Journal of Gastroenterology, 2006, .	0.4	2
72	Adipokines in NASH: Postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology, 2005, 42, 1175-1183.	7.3	253

#	ARTICLE	IF	CITATIONS
73	Hypoadiponectinemia Predicts the Severity of Hepatic Fibrosis and Pancreatic Beta-Cell Dysfunction in Nondiabetic Nonobese Patients with Nonalcoholic Steatohepatitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 2438-2446.	0.4	185
74	Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2003, 37, 909-916.	7.3	621
75	Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. <i>Hepatology</i> , 2002, 35, 367-372.	7.3	644
76	Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. <i>Lipids</i> , 2001, 36, 1117-1124.	1.7	83